Login to Your Account

ASCO 2012

Regulatory Filings Next Step for Ariad's Ponatinib in CML

By Marie Powers
Staff Writer

Tuesday, June 5, 2012
Ariad Pharmaceuticals Inc. used the American Society of Clinical Oncology's (ASCO) annual meeting in Chicago as its forum to confirm that the next steps for its investigational pan-BCR-ABL inhibitor, ponatinib, will be regulatory filings in the U.S. and Europe, expected in the third quarter.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription